


## Data Sheet

<b>Product Name:</b>	LAT1-IN-1
<b>Cat. No.:</b>	CS-0029110
<b>CAS No.:</b>	20448-79-7
<b>Molecular Formula:</b>	C <sub>8</sub> H <sub>13</sub> NO <sub>2</sub>
<b>Molecular Weight:</b>	155.19
<b>Target:</b>	Apoptosis
<b>Pathway:</b>	Apoptosis
<b>Solubility:</b>	DMSO : < 1 mg/mL (insoluble or slightly soluble); H <sub>2</sub> O : 41.67 mg/mL (268.51 mM; Need ultrasonic)



### BIOLOGICAL ACTIVITY:

LAT1-IN-1 (BCH) is a selective and competitive inhibitor of **large neutral amino acid transporter 1 (LAT1)** significantly inhibit cellular uptake of amino acids and **mTOR** phosphorylation, which induces the suppression of cancer growth and **apoptosis**<sup>[1][2][3]</sup>. IC<sub>50</sub> & Target: LAT1<sup>[1]</sup> **In Vitro:** LAT1-IN-1 (1-100 mM; 3 days; KYSE30 and KYSE150 esophageal cancer cells) treatment suppresses cell proliferation in a dose-dependent manner<sup>[1]</sup>.

LAT1-IN-1 (30 mM; 24 and 48 hours; KYSE30 and KYSE150 cells) treatment significantly increases cell population in the G<sub>0</sub>/G<sub>1</sub> phase in both KYSE30 and KYSE150 cells, indicating that LAT1-IN-1 induces cell cycle arrest at G<sub>1</sub> phase<sup>[1]</sup>.

LAT1-IN-1 (30 mM; 0-24 hours; KYSE30 and KYSE150 cells) treatment decreases phosphorylation of 4E-BP1 and p70S6K at 30 minutes and the decrease is continued for 24 hours. The amount of mTOR, 4E-BP1, and p70S6K proteins is slightly decreased<sup>[1]</sup>. **In**

**Vivo:** LAT1-IN-1 (200 mg/kg; intravenous injection; daily; for 14 days; male BALB/c nude mice) treatment significantly delays tumor growth and decreases glucose metabolism, indicating that LAT1 inhibition potentially suppresses esophageal cancer growth in vivo<sup>[1]</sup>.

### References:

[1]. Ohshima Y, et al. Efficacy of system I amino acid transporter 1 inhibition as a therapeutic target in esophageal squamous cell carcinoma. *Cancer Sci.* 2016 Oct;107(10):1499-1505.

[2]. Singh N, et al. Discovery of Potent Inhibitors for the Large Neutral Amino Acid Transporter 1 (LAT1) by Structure-Based Methods. *Int J Mol Sci.* 2018 Dec 21;20(1).

[3]. Wang Q, et al. L-type amino acid transport and cancer: targeting the mTORC1 pathway to inhibit neoplasia. *Am J Cancer Res.* 2015 Mar 15;5(4):1281-94. eCollection 2015.

### CAIndexNames:

Bicyclo[2.2.1]heptane-2-carboxylic acid, 2-amino-

### SMILES:

O=C(C1(N)C(C2)CCC2C1)O

**Caution: Product has not been fully validated for medical applications. For research use only.**

Tel: 610-426-3128

Fax: 888-484-5008

E-mail: [sales@ChemScene.com](mailto:sales@ChemScene.com)

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA